The MEK inhibitor binimetinib improved progression - free survival compared with dacarbazine in patients with NRAS - mutant melanoma, according to the results of the NEMO trial. (cancernetwork.com)
Current treatments for melanoma patients include dacarbazine and temozolomide, which have an unsatisfactory response rate. (sciencedaily.com)
After frustrating decades of little progress, the landscape of melanoma therapy was dramatically altered with the first report in 2010 of significantly improved overall survival with the cytotoxic T - lymphocyte — associated antigen 4 (CTLA - 4) inhibitor ipilimumab, compared with a vaccine, and subsequently, compared with the then «standard» chemotherapeutic agent dacarbazine (DTIC). (cancernetwork.com)